Skip to main content
Healthcare

Healthcare Concentration Risk: Subsector and Holdings Analysis

Pomegra Learn

How Concentrated Is Healthcare, and What Are the Risks?

Healthcare sector concentration has increased significantly as a consequence of the GLP-1 revolution — Eli Lilly's market cap appreciation from approximately 2020 to 2024 grew its XLV weight from approximately 2–3% to approximately 8–10%, while UnitedHealth Group's weight has consistently represented approximately 8–10% of the ETF. Together, these two companies represent approximately 18–22% of the XLV benchmark — a concentration profile that means investors expecting "broad Healthcare exposure" are meaningfully expressing views on two specific companies. Understanding this concentration, how it has changed over time, and what alternative vehicles reduce single-stock exposure helps investors manage Healthcare allocation risk.

Quick definition: Healthcare sector concentration risk arises from market-cap-weighted indices: XLV's top two holdings (UnitedHealth Group and Eli Lilly) together represent approximately 18–22% of the ETF, meaning substantial Healthcare exposure is implicitly a concentrated bet on a managed care conglomerate and a GLP-1 drug manufacturer. This concentration increases when large-cap Healthcare companies appreciate significantly relative to sector peers.

Key takeaways​

  • UnitedHealth Group has consistently represented approximately 8–10% of XLV — the largest single-name Healthcare weight, making XLV performance substantially tied to managed care industry dynamics
  • Eli Lilly's XLV weight grew from approximately 2–3% (2020) to approximately 8–10% (2024) as GLP-1 obesity drug enthusiasm drove approximately 300%+ appreciation — a dynamic weight shift that fundamentally altered XLV's exposure profile
  • The top 10 XLV holdings typically represent approximately 55–65% of the ETF — broad Healthcare sector exposure is a misnomer; XLV is heavily weighted toward a handful of large-cap Healthcare companies
  • VHT (Vanguard Healthcare ETF) has similar concentration characteristics to XLV — both track S&P Healthcare indices with market-cap weighting
  • Equal-weight Healthcare alternatives (RSPH — Invesco S&P 500 Equal Weight Health Care ETF) significantly reduce single-stock concentration but shift exposure toward smaller-cap Healthcare companies

UnitedHealth's persistent dominance​

Market cap and XLV weight: UnitedHealth Group, with a market cap consistently above $400–500 billion, is the largest Healthcare company in the US by market cap and therefore the largest XLV weight. At approximately 8–10%, a $1,000 XLV position has approximately $80–100 in UnitedHealth exposure — the equivalent of a significant direct holding in a single managed care conglomerate.

UnitedHealth's diverse business: UnitedHealth's weight in XLV represents exposure to managed care insurance, pharmacy benefit management (OptumRx), physician groups and surgical centers (OptumHealth), health analytics (OptumInsight), and healthcare banking (Optum Bank). This diversification within UnitedHealth means XLV investors are exposed to multiple healthcare delivery mechanisms through a single holding — but regulatory risk, management execution risk, and Medicare Advantage reimbursement risk are concentrated in one entity.

When UnitedHealth drives XLV: The impact of UnitedHealth's single-stock moves on XLV is material. When UnitedHealth declines 10% on elevated medical loss ratio news, XLV absorbs approximately 0.8–1.0 percentage points of that decline. XLV investors who perceive themselves as gaining Healthcare sector exposure may be surprised by the managed care-specific nature of these moves.

The CEO transition risk: UnitedHealth experienced a significant corporate governance shock in late 2024 when its CEO was killed — a unique and unprecedented event that caused substantial stock and sector disruption. This event illustrated a tail risk that concentrated single-stock exposure creates: events specific to a single company generating outsized sector ETF impact.

Eli Lilly's dynamic weight growth​

GLP-1 appreciation and weight trajectory: Eli Lilly's XLV weight growth from approximately 2–3% in early 2020 to approximately 8–10% by 2024 represents one of the most dramatic index weight shifts in modern sector ETF history. An investor who purchased XLV in 2020 expecting pharmaceutical and managed care sector exposure found that their holding had substantially transformed into a GLP-1 drug company play as Lilly's appreciation dominated sector returns.

XLV as GLP-1 proxy: By 2024, XLV's performance was substantially correlated with Eli Lilly's stock performance — positive GLP-1 clinical data, manufacturing capacity announcements, and competitive dynamics with Novo Nordisk were driving meaningful XLV moves. Investors using XLV as a recession hedge or defensive allocation found themselves exposed to a high-multiple growth theme driven by obesity drug dynamics.

Weight rebalancing mechanics: Market-cap-weighted indices like XLV rebalance when the underlying S&P Healthcare Index reconstitutes (typically semi-annually). Companies that appreciate significantly grow their index weights between reconstitutions; on reconstitution dates, weights are reset to market-cap proportional levels. This means that between reconstitution dates, a stock that appreciates 100% would grow its weight proportionally — creating momentum exposure that is only partially reset.

Concentration risk if Lilly disappoints: The flip side of Lilly's weight growth is that a significant Lilly disappointment (GLP-1 clinical setback, competitive dynamics shift, manufacturing problem) would generate outsized XLV impact. An investor in XLV for defensive healthcare exposure could experience a 10%+ XLV drawdown from a single pharmaceutical company event — not the broad sector diversification they may have expected.

How it flows​

Subsector weight evolution​

Pharmaceutical weight trends: Large pharmaceutical companies (J&J, Pfizer, Merck, AbbVie, Bristol-Myers Squibb) collectively represented a larger XLV weight in prior decades when pharmaceutical market caps were larger relative to managed care and biotech. As managed care companies (UnitedHealth, Humana, Elevance, Cigna) grew in market cap through enrollment expansion and Optum-style vertical integration, the pharmaceutical weight share declined.

Managed care weight growth: The managed care subsector's XLV weight has grown significantly from the early 2010s through the 2020s — reflecting both enrollment growth (ACA expansion, Medicare Advantage growth) and per-member profitability expansion. UnitedHealth alone represented approximately 10% of the S&P Healthcare Index by 2024 — up from approximately 4–6% in the early 2010s.

Biotech's modest weight: Despite generating some of the sector's most dramatic individual stock performances, biotech companies represent a relatively small weight in XLV. Large commercial biotech (Amgen, Gilead, Regeneron, Vertex) each represent approximately 2–4% weights; development-stage biotech companies have market caps that place them at minimal XLV weights. The biotech bull market's impact on XLV is muted by this structure.

Device sector weight: Medical device companies (Abbott, Medtronic, Becton Dickinson, Stryker, Intuitive Surgical, Edwards Lifesciences) collectively represent approximately 15–20% of XLV — a meaningful but not dominant subsector weight. Device weight is relatively stable as device companies grow through procedure volume growth and acquisition rather than the explosive market cap appreciation that pharmaceutical companies experience on major drug approvals.

Concentration management approaches​

Equal-weight alternative (RSPH): Invesco's RSPH ETF (S&P 500 Equal Weight Health Care) weights each S&P 500 Healthcare company equally — eliminating the concentration risk from UnitedHealth and Eli Lilly. Equal weighting increases exposure to smaller Healthcare companies and reduces the GLP-1 theme concentration in XLV. RSPH underperformed XLV significantly during 2023–2024 as Lilly's appreciation dominated XLV returns.

Subsector ETFs to reduce concentration: Investors with views on specific Healthcare subsectors can combine subsector ETFs — IHI (devices), IHF (managed care), pharmaceutical-focused funds — to construct a Healthcare allocation with customized subsector weights. This approach allows reduction of managed care or pharmaceutical concentration while adding device or specialty pharmaceutical exposure.

Direct indexing: Investors with sufficient assets can implement direct Healthcare indexing — holding individual Healthcare stocks in proportion to their desired weights rather than through an ETF. This allows precise concentration management: capping UnitedHealth at 5% rather than 10%, excluding Eli Lilly if the GLP-1 thesis is not part of the Healthcare investment thesis.

Position-level tracking: XLV investors who want to understand their actual single-stock exposures should regularly review XLV's published holdings list (available from State Street at ssga.com) — concentrations change over time as market caps evolve. Annual or semi-annual reviews of XLV's current holdings distribution prevent surprises from dynamic weight changes.

Cross-sector concentration considerations​

Healthcare in the S&P 500: Healthcare represents approximately 12–14% of the S&P 500 — the third or fourth largest sector weight (varying with relative sector performance). Investors holding the full S&P 500 already have significant Healthcare exposure; additional tactical Healthcare allocation adds incremental exposure on top of the benchmark weight.

Double-counting within portfolios: Portfolio investors who hold both an S&P 500 ETF and an XLV allocation may have more UnitedHealth and Eli Lilly concentration than intended. A $100,000 S&P 500 position includes approximately 1.0–1.5% UnitedHealth exposure (approximately $1,000–1,500); adding $20,000 in XLV adds another approximately $1,600–2,000 in UnitedHealth exposure — creating approximately 2.5–3.5% effective UnitedHealth weight in the combined portfolio.

Common mistakes​

Assuming XLV provides subsector diversification equivalent to the full Healthcare sector. XLV's top-10 concentration of approximately 55–65% means that most of the ETF's performance attribution comes from a handful of large-cap Healthcare companies. The equal-weight Healthcare index (RSPH) provides substantially different exposure — more representative of the full Healthcare company universe but with different return characteristics.

Not updating concentration assessment as market caps evolve. Eli Lilly's weight growth from 2020 to 2024 happened gradually and continuously — investors who assessed XLV's concentration in 2020 and did not update their assessment were unknowingly absorbing increasingly large GLP-1 exposure. Concentration profiles in market-cap-weighted ETFs require periodic reassessment, particularly when individual holdings are appreciating dramatically.

FAQ​

How does XLV's concentration compare to other sector ETFs?​

XLV's concentration (top 2 holdings approximately 18–22%) is moderate relative to other sector ETFs. The Technology sector ETF (XLK) has had even higher top-2 concentration (Apple and Microsoft representing 40%+). Consumer Discretionary (XLY) has had Amazon and Tesla at approximately 35–40% combined. Healthcare's concentration is meaningful but not extreme by sector ETF standards. Current holdings and weights for all SPDR Sector ETFs are available at ssga.com.

Summary​

Healthcare sector concentration has intensified as UnitedHealth Group (approximately 8–10% XLV weight) and Eli Lilly (approximately 8–10%, grown from approximately 2–3% through GLP-1 appreciation) together represent approximately 18–22% of XLV. This concentration means that broad Healthcare ETF exposure is substantially a bet on managed care dynamics and GLP-1 obesity drug commercial success. Top-10 holdings represent approximately 55–65% of XLV — the sector's apparent diversification is more limited than investors may expect. Equal-weight alternatives (RSPH) reduce single-stock concentration but shift exposure toward smaller-cap Healthcare companies. Investors should regularly review XLV's current holdings distribution — Eli Lilly's dynamic weight growth illustrates how market-cap-weighted Healthcare exposure can shift substantially without any portfolio action from the investor.

Next​

→ Healthcare Supply Chain: Drug Manufacturing and Distribution